Exenatide
Exenatide, sold under the brand name Byetta among others, is a medication used to treat type 2 diabetes. It is used together with diet, exercise, and potentially other antidiabetic medication. It is a treatment option after metformin and sulfonylureas. It is given by injection under the skin.
Clinical data | |
---|---|
Pronunciation | /ɛɡzˈɛnətaɪd/ ⓘ |
Trade names | Byetta, Bydureon, Bydureon BCise, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a605034 |
License data | |
Pregnancy category |
|
Routes of administration | Subcutaneous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | N/A |
Metabolism | proteolysis |
Elimination half-life | 2.4 h |
Excretion | Kidney |
Identifiers | |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.212.123 |
Chemical and physical data | |
Formula | C184H282N50O60S |
Molar mass | 4186.63 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
| |
(what is this?) (verify) |
Common side effects include low blood sugar, nausea, dizziness, abdominal pain, and pain at the site of injection. Other serious side effects may include medullary thyroid cancer, angioedema, pancreatitis, and kidney injury. Use in pregnancy and breastfeeding is of unclear safety. Exenatide is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) also known as incretin mimetics. It works by increasing insulin release from the pancreas and decreases excessive glucagon release.
Exenatide was approved for medical use in the United States in 2005. In 2019, it was the 312th most commonly prescribed medication in the United States, with more than 1 million prescriptions.